Real-world experience of palbociclib and ribociclib: novel oral therapy in metastatic breast cancer.
Sign Up to like & getrecommendations! Published in 2020 at "International Journal of Clinical Pharmacy"
DOI: 10.1007/s11096-020-01193-z
Abstract: Background Palbociclib and ribociclib are novel oral agents in hormone receptor-positive metastatic breast cancer. Neutropenia is a common adverse event associated with these treatments and its clinical management often requires regimen changes, such as cycle… read more here.
Keywords: regimen changes; palbociclib; metastatic breast; breast cancer ... See more keywords